State Street Corp Trims Stake in Immunome, Inc. (NASDAQ:IMNM)

State Street Corp cut its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 7.5% in the third quarter, HoldingsChannel reports. The firm owned 2,187,466 shares of the company’s stock after selling 176,768 shares during the period. State Street Corp’s holdings in Immunome were worth $31,981,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. FMR LLC lifted its position in shares of Immunome by 0.3% in the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares during the period. Janus Henderson Group PLC lifted its holdings in Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after buying an additional 324,614 shares during the period. Marshall Wace LLP boosted its position in Immunome by 228.5% during the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after acquiring an additional 1,191,774 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Immunome by 48.1% in the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after acquiring an additional 237,497 shares during the period. Finally, Sofinnova Investments Inc. raised its position in shares of Immunome by 10.3% in the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock worth $7,934,000 after acquiring an additional 61,284 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Clay B. Siegall purchased 66,057 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the purchase, the chief executive officer now owns 485,693 shares in the company, valued at $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Lechleider acquired 15,805 shares of Immunome stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, with a total value of $149,831.40. Following the completion of the purchase, the insider now owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 102,862 shares of company stock worth $978,045 over the last 90 days. 8.60% of the stock is currently owned by corporate insiders.

Immunome Stock Performance

Immunome stock opened at $10.97 on Friday. The stock has a market cap of $684.71 million, a PE ratio of -1.35 and a beta of 1.83. The stock has a 50-day moving average of $12.14 and a two-hundred day moving average of $13.35. Immunome, Inc. has a one year low of $8.15 and a one year high of $30.96.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IMNM. Piper Sandler dropped their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Finally, Stephens assumed coverage on shares of Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $28.83.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.